A trial of pembrolizumab and chemotherapy for triple negative breast cancer (Keynote-355)

This trial was for people with triple negative breast cancer that had come back or spread to another part of the body.

Triple negative breast cancer means cancer that doesn’t have receptors for:

• the hormone oestrogen

• the hormone progesterone

• the protein HER2

People could join the trial between 2017 and 2018. The team published results between 2020 and 2024.

There is a link to more information in the ‘Summary of results’ section below.